Compare COO & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | ALGN |
|---|---|---|
| Founded | 1980 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.3B |
| IPO Year | 1994 | 2000 |
| Metric | COO | ALGN |
|---|---|---|
| Price | $57.36 | $145.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 16 |
| Target Price | $66.21 | ★ $206.36 |
| AVG Volume (30 Days) | ★ 4.7M | 752.2K |
| Earning Date | 09-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.53 |
| EPS | 2.49 | ★ 3.09 |
| Revenue | ★ $2,532,800,000.00 | $387,126,000.00 |
| Revenue This Year | $3.58 | $3.22 |
| Revenue Next Year | $4.07 | $4.07 |
| P/E Ratio | ★ $22.69 | $46.46 |
| Revenue Growth | 18.41 | ★ 23.95 |
| 52 Week Low | $51.01 | $124.91 |
| 52 Week High | $89.83 | $200.44 |
| Indicator | COO | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.88 | 38.25 |
| Support Level | $51.01 | N/A |
| Resistance Level | $73.39 | $154.10 |
| Average True Range (ATR) | 1.48 | 4.09 |
| MACD | 0.63 | 0.15 |
| Stochastic Oscillator | 82.68 | 22.05 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.